Merck to acquire San Diego biotech company Prometheus Biosciences for $10.8 billion

Under the terms of the deal announced Sunday, Merck (NYSE: MRK) will acquire Prometheus Biosciences (NASDAQ: RXDX) for $200 per share in cash.